Skip to main content
QuestionsResearchTagsGuidelinesLeaderboard
tachyDx Research Portal

Research tagged [nephrology]

Every paper is generated from a real clinical discussion on tachyDx, peer-reviewed by verified physicians, and published with a unique TDX identifier. All contributors are credited.

DOIs registered viaCrossref
Published26Under ReviewFlagged
Clear filters

4 papers

TDX-2026-00017

Desensitization Strategies for Highly Sensitized Kidney Transplant Candidates with High-Titer Donor-Specific Antibodies: A Clinical Consensus and Evidence Review

Highly sensitized kidney transplant candidates, characterized by elevated calculated panel reactive antibody (cPRA) and high-titer donor-specific antibodies (DSA), face significant barriers to transplantation. This paper synthesizes expert clinical practice and current evidence regarding desensitization protocols for such challenging cases. Utilizing a community peer-reviewed clinical Q&A platform (tachyDx), expert opinions from two verified physicians, supported by 71 community votes, were analyzed to address critical questions concerning desensitization protocols for mean fluorescence intensity (MFI) >10,000, the role of imlifidase, and acceptable MFI thresholds for transplantation. **Background:** Highly sensitized kidney transplant candidates, often with a history of failed transplants, experience prolonged wait times and increased risk of antibody-mediated rejection (AMR). Effective desensitization protocols are crucial for expanding transplant access in this population. **Methods:** A clinical scenario involving a 34-year-old female with ESRD, cPRA 98%, and multiple high-titer DSAs (MFI up to 14,500) against a potential living donor was presented on the tachyDx platform. Two board-certified nephrology and transplant medicine specialists provided detailed responses, which were then peer-voted by 71 community physicians. This paper formally synthesizes these expert recommendations and integrates them with established medical literature. **Results:** A modified Johns Hopkins desensitization protocol, incorporating bortezomib, dexamethasone, plasmapheresis, IVIG, and rituximab, was proposed for MFI >10,000, demonstrating a 4/6 success rate in achieving transplantable MFI levels. Imlifidase (IdeS) was identified as a transformative rescue strategy, capable of rapidly cleaving IgG antibodies, with reported conversion rates to negative crossmatch exceeding 90% in clinical trials. Critical MFI thresholds for acceptable risk were defined as <5,000 for Class I and <3,000 for Class II DSA (particularly DQ), coupled with negative flow cytometry and C1q binding assays. DQ antibodies were highlighted as a significant concern due to their strong association with AMR. **Conclusions:** Effective management of highly sensitized kidney transplant candidates requires multi-agent desensitization strategies, judicious use of novel agents like imlifidase, and stringent MFI thresholds. Individualized protocols and close post-transplant monitoring are essential to mitigate the risk of AMR and improve graft outcomes in this complex patient population.

A physician-only Q&A platform where verified medical doctors share clinical knowledge, debate evidence, and build the knowledge base the world needs.

Powered by

Platform

  • Questions
  • Research
  • Tags
  • Guidelines
  • Leaderboard
  • Report a Bug

Ecosystem

  • Teams
  • Sponsors
  • Hiring
  • Publishing
  • CME
  • Data

Company

  • About
  • Support
  • Privacy Policy
  • Terms of Service
  • Contact

© 2026 Aethryva Deeptech Pvt Ltd. All rights reserved.

Crossref Member
2 contributors 71 votes 9 Apr 2026

TDX-2026-00016

Optimizing Potassium Replacement and Insulin Initiation in Diabetic Ketoacidosis with Initial Hypokalemia: A Peer-Reviewed Clinical Consensus

Background: Diabetic ketoacidosis (DKA) is a severe metabolic emergency characterized by hyperglycemia, ketonemia, and acidosis. Despite the extracellular shift of potassium (K+) in acidosis, initial hypokalemia is observed in a significant proportion of DKA patients, indicating a profound total body K+ deficit. The timing of insulin initiation in such cases presents a critical clinical dilemma, balancing the urgent need for acidosis correction against the risk of precipitous K+ decline and subsequent cardiac arrhythmias. Methods: This consensus paper synthesizes expert opinion from two verified physicians within the tachyDx peer-review community, supported by 72 community peer votes. The discussion focused on a 28-year-old male presenting with DKA and initial serum K+ of 3.1 mEq/L. Key areas of inquiry included the aggressiveness and route of K+ replacement, concurrent K+ infusion rates with insulin, and the role of phosphate and magnesium supplementation. Results: A consensus emerged advocating for aggressive K+ replacement (e.g., 40 mEq KCl via central line over 1 hour) prior to insulin initiation, with a recommended threshold of K+ ≥ 3.5 mEq/L. Central venous access was preferred for high-rate infusions, with peripheral alternatives outlined. Concurrent K+ infusion at 20-40 mEq/hr was advised during insulin therapy, targeting serum K+ of 4.0-5.0 mEq/L. Modified insulin dosing (0.05 units/kg/hr) was suggested for K+ < 3.5 mEq/L. The importance of magnesium monitoring and replacement, alongside judicious potassium phosphate use for hypophosphatemia, was emphasized. Bicarbonate administration was generally discouraged. Conclusions: This peer-reviewed consensus provides practical, evidence-informed guidance for managing initial hypokalemia in DKA. The recommendations prioritize patient safety by mitigating arrhythmia risk while facilitating timely DKA resolution, offering a refined approach to electrolyte management in this complex clinical scenario.

2 contributors 72 votes 6 Apr 2026

TDX-2026-00005

Interpreting Elevated Cardiac Troponin in Chronic Kidney Disease: An Evidence-Based Framework from Community Peer Consensus

Background: The interpretation of elevated cardiac troponin levels in patients with chronic kidney disease (CKD) presents a significant diagnostic challenge in acute care settings. CKD patients frequently exhibit chronically elevated baseline troponin, complicating the differentiation between acute myocardial infarction (AMI), demand ischemia, and non-ischemic myocardial injury. This ambiguity often leads to diagnostic delays or inappropriate interventions, particularly in the context of atypical symptoms and a desire for early discharge. Methods: This consensus paper synthesizes expert opinions and clinical insights from a peer-reviewed discussion involving four verified physicians (emergency medicine, cardiology, nephrology, internal medicine) on the tachyDx platform, which garnered 73 community peer votes. The methodology involved structured responses to a clinical dilemma, followed by expert review and synthesis. Results: Key findings include the utility of an absolute delta troponin rise of ≥0.05 ng/mL over 3-6 hours, integrated with clinical context, to warrant urgent cardiac evaluation. High-sensitivity troponin assays were deemed more useful in CKD when serial measurements and CKD-specific cutoffs are applied. CT coronary angiography serves as a valuable gatekeeper for intermediate-risk patients with adequate renal function (eGFR ≥30 mL/min/1.73m²), while pharmacologic stress testing is preferred for advanced CKD. A structured risk stratification approach was developed, emphasizing the integration of ECG, hemodynamic status, and symptomology. Conclusions: An integrated, multi-modal approach, combining serial high-sensitivity troponin measurements with an absolute delta threshold, careful clinical assessment, and judicious use of advanced imaging, is crucial for accurate risk stratification and management of CKD patients with suspected acute coronary syndromes. Effective patient communication regarding diagnostic timelines is also vital.

4 contributors 73 votes 6 Apr 2026

TDX-2026-00002

Optimizing SGLT2 Inhibitor Initiation in Acute Decompensated Heart Failure with Reduced Ejection Fraction: A Multi-Specialty Clinical Consensus

Background: Sodium-glucose co-transporter 2 (SGLT2) inhibitors have demonstrated significant benefits in chronic heart failure with reduced ejection fraction (HFrEF) and, more recently, in acute decompensated heart failure (ADHF). However, practical guidance regarding their initiation during ADHF hospitalization, particularly in patients with concomitant renal impairment, remains a subject of clinical debate. This consensus paper synthesizes expert opinion on critical aspects of SGLT2 inhibitor use in this acute setting. Methods: This study utilized a community peer-review methodology facilitated by the tachyDx platform. A clinical scenario involving a 68-year-old female with ADHF-HFrEF and an eGFR of 32 mL/min/1.73m² was presented to a panel of four verified physicians (Cardiology, Nephrology, Internal Medicine). Their responses, addressing specific questions on eGFR thresholds, renal monitoring, AKI risk, and agent selection, were subjected to peer voting by 89 community physicians, establishing a consensus-driven framework. Results: Consensus emerged for SGLT2 inhibitor initiation at eGFR thresholds as low as 20-25 mL/min/1.73m², provided hemodynamic stability and euvolemia are achieved. Renal function monitoring at 48 hours and 7 days post-initiation was recommended, with an expected initial eGFR dip of 3-5 mL/min. The perceived risk of acute kidney injury (AKI) was primarily attributed to volume depletion rather than direct drug effect, necessitating concomitant loop diuretic dose reduction (20-30%). Full-dose initiation was advocated once patients were stable (off vasopressors/inotropes for 24 hours, stable diuretics). Euglycemic diabetic ketoacidosis was identified as a rare but significant concern, particularly in nutritionally compromised patients. Conclusions: This multi-specialty consensus supports the early initiation of SGLT2 inhibitors in hemodynamically stable ADHF-HFrEF patients, even with moderate renal impairment, emphasizing careful volume management and renal monitoring. These findings provide practical, evidence-informed guidance for clinicians navigating the complexities of SGLT2 inhibitor use in the acute care setting.

4 contributors 89 votes 6 Apr 2026
Page 1 of 2Next →

Topics

Allpharmacology8critical-care7cardiology6emergency-medicine6oncology5pulmonology5nephrology4neurology4gastroenterology3immunology3hematology3surgery3infectious-disease3radiology2endocrinology2anesthesiology2hepatology2pediatrics2rheumatology2evidence-based-medicine1orthopedics1trauma1neonatology1psychiatry1internal-medicine1